PT  - JOURNAL ARTICLE
AU  - Andrea G. Edlow
AU  - Victor M. Castro
AU  - Lydia L. Shook
AU  - Anjali J. Kaimal
AU  - Roy H. Perlis
TI  - Neurodevelopmental outcomes at one year in offspring of mothers who test positive for SARS-CoV-2 during pregnancy
AID  - 10.1101/2021.12.15.21267849
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.15.21267849
4099  - http://medrxiv.org/content/early/2021/12/16/2021.12.15.21267849.short
4100  - http://medrxiv.org/content/early/2021/12/16/2021.12.15.21267849.full
AB  - Importance Epidemiologic studies suggest maternal immune activation during pregnancy may be associated with neurodevelopmental effects in offspring.Objective To determine whether in utero exposure to the novel coronavirus SARS-CoV-2 is associated with risk for neurodevelopmental disorders in the first 12 months after birth.Design Retrospective cohortParticipants Live offspring of all mothers who delivered between March and September 2020 at one of six Massachusetts hospitals across two health systems.Exposure SARS-CoV-2 infection confirmed by PCR during pregnancyMain Outcome and Measures Neurodevelopmental disorders determined from ICD-10 diagnostic codes over 12 months; sociodemographic and clinical features of mothers and offspring; all drawn from the electronic health record.Results The cohort included 7,772 live births (7,466 pregnancies, 96% singleton, 222 births to SARS-CoV-2 positive mothers), with mean maternal age of 32.9 years; offspring were 9.9% Asian, 8.4% Black, and 69.0% white; 15.1% were of Hispanic ethnicity. Preterm delivery was more likely among exposed mothers (14% versus 8.7%; p=.003). Maternal SARS-CoV-2 positivity during pregnancy was associated with greater rate of neurodevelopmental diagnoses (crude OR 2.17 [95% CI 1.24-3.79, p=0.006]) as well as models adjusted for race, ethnicity, insurance status, offspring sex, maternal age, and preterm status (adjusted OR 1.86 [95% CI 1.03-3.36, p=0.04]). Third-trimester infection was associated with effects of larger magnitude (adjusted OR 2.34, 95% CI 1.23-4.44, p=0.01)Conclusion and Relevance Our results provide preliminary evidence that maternal SARS-CoV-2 may be associated with neurodevelopmental sequelae in some offspring. Prospective studies with longer follow-up duration will be required to exclude confounding and confirm these effects.Trial Registration NAQuestion Does COVID-19 exposure in utero increase the risk for neurodevelopmental disorders in the first year of life?Findings In a cohort of babies delivered during COVID-19, those born to mothers with a positive SARS-CoV-2 PCR test during pregnancy were more likely to receive a neurodevelopmental diagnosis in the first 12 months after delivery, even after accounting for preterm delivery.Meaning These preliminary findings suggest that COVID-19 exposure may impact neurodevelopment, and highlight the need for prospective investigation of outcomes in children exposed to COVID-19 in utero.Competing Interest StatementDr. Perlis has received consulting fees from Burrage Capital, Genomind, RID Ventures, Belle Artificial Intelligence, and Takeda. He holds equity in Psy Therapeutics, Belle Artificial Intelligence, and Circular Genomics. The other authors report no disclosures.Funding StatementThis study was supported by the National Institute of Mental Health (R01MH116270 and 1R56MH115187; Dr. Perlis) and the National Institute of Child Health and Human Development (R01 HD100022-02S2; Dr. Edlow).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mass General-Brigham Institutional Review Board approved all aspects of this studyI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not available for external release.